Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha 2b inhalation - Altum Pharmaceuticals/BetterLife Pharma

Next Previous
Drug Profile

Interferon alpha 2b inhalation - Altum Pharmaceuticals/BetterLife Pharma

Alternative Names: AntiCovir; AP 003 - Altum Pharmaceuticals; Interferon alpha 2b inhalation - BetterLife Pharma; MM-003; recombinant human interferon alpha-2b - BetterLife Pharma; rhIFNa2b - BetterLife Pharma

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altum Pharmaceuticals; Unknown
  • Developer Altum Pharmaceuticals; BetterLife Pharma; Pontifical Catholic University of Chile
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon alpha-2 replacements; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in China (Inhalation)
  • 05 Aug 2022 Altum Pharmaceuticals completes phase I/II trials in COVID-2019 infections (In volunteers) in Chile (Inhalation) (NCT04988217)
  • 29 Nov 2021 Phase-II clinical trials in COVID-2019 infections in Chile (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top